Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gynecologic 4Thoracic 3Gastrointestinal 3Dermatologic 3Breast 3Sarcoma 2Plasma cell 1Head & Neck 1CNS 1

Conditions

Neuroblastoma 17Glioblastoma 11Melanoma 5Brain Neoplasms 5Rhabdoid Tumor 4Osteosarcoma 4Lymphoma 4Glioma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Ovarian Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Wilms Tumor 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2Neurofibromatosis 1 2Neuroectodermal Tumors, Primitive 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Meningioma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Leukemia, Myelomonocytic, Juvenile 2Hepatoblastoma 2

Interventions

Docetaxel 5Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3ulixertinib 2X-Rays 2Trastuzumab 2Radiotherapy 2Filgrastim 2FAPI-46 2Carboplatin 2vocimagene amiretrorepvec 1trastuzumab biosimilar HLX02 1trametinib 1tovorafenib 1tipifarnib 1tanespimycin 1sapanisertib 1sacituzumab govitecan 1romidepsin 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1oblimersen 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × fludarabine × CNS × Clear all
NCT02457650 2016-08-03

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Shenzhen Second People's Hospital

Phase 1 Unknown
36 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Melanoma, Multiple Myeloma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡